×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
NVO – novo nordisk a/s (US:NYSE)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
NVO
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/24
08:03 pm
nvo
Form Health Named to Fast Company's Annual List of the World's Most Innovative Companies of 2026 [Yahoo! Finance]
Neutral
Report
Form Health Named to Fast Company's Annual List of the World's Most Innovative Companies of 2026 [Yahoo! Finance]
3/24
12:25 pm
nvo
Jefferies trims Novo Nordisk target as GLP-1 pricing erosion and oral Wegovy launch uncertainty cloud first quarter [Yahoo! Finance]
Low
Report
Jefferies trims Novo Nordisk target as GLP-1 pricing erosion and oral Wegovy launch uncertainty cloud first quarter [Yahoo! Finance]
3/24
11:33 am
nvo
Greater weight loss promised by higher-dose Wegovy shot, now approved by FDA [FOX News]
Low
Report
Greater weight loss promised by higher-dose Wegovy shot, now approved by FDA [FOX News]
3/24
06:13 am
nvo
iDEL Therapeutics Appoints Claudia Ulbrich as Chair of its Board of Directors [TheStreet.com]
Low
Report
iDEL Therapeutics Appoints Claudia Ulbrich as Chair of its Board of Directors [TheStreet.com]
3/24
06:12 am
nvo
iDEL Therapeutics Appoints Claudia Ulbrich as Chair of its Board of Directors [Yahoo! Finance]
Low
Report
iDEL Therapeutics Appoints Claudia Ulbrich as Chair of its Board of Directors [Yahoo! Finance]
3/23
07:58 pm
nvo
As demand for GLP-1 pills and shots surges, healthy habits are still key [Los Angeles Times (CA)]
Low
Report
As demand for GLP-1 pills and shots surges, healthy habits are still key [Los Angeles Times (CA)]
3/23
03:43 pm
nvo
India Opened the Floodgates on Weight-Loss Generics [Yahoo! Finance]
Low
Report
India Opened the Floodgates on Weight-Loss Generics [Yahoo! Finance]
3/23
02:00 pm
nvo
GLP-1 Race Heats Up with Positive Test Results for Next-Gen Eli Lilly Drug [Yahoo! Finance]
Low
Report
GLP-1 Race Heats Up with Positive Test Results for Next-Gen Eli Lilly Drug [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
3/23
08:56 am
nvo
Form 6-K NOVO NORDISK A S For: Mar 23
Low
Report
Form 6-K NOVO NORDISK A S For: Mar 23
3/20
08:12 am
nvo
Form 6-K NOVO NORDISK A S For: Mar 19
Low
Report
Form 6-K NOVO NORDISK A S For: Mar 19
3/17
07:11 am
nvo
Form 6-K NOVO NORDISK A S For: Mar 16
Low
Report
Form 6-K NOVO NORDISK A S For: Mar 16
3/9
07:53 am
nvo
Form 6-K NOVO NORDISK A S For: Mar 09
Low
Report
Form 6-K NOVO NORDISK A S For: Mar 09
3/2
11:48 am
nvo
Form 6-K NOVO NORDISK A S For: Mar 02
Low
Report
Form 6-K NOVO NORDISK A S For: Mar 02
3/2
07:57 am
nvo
Form 6-K NOVO NORDISK A S For: Mar 02
Low
Report
Form 6-K NOVO NORDISK A S For: Mar 02
2/23
08:19 am
nvo
Form 6-K NOVO NORDISK A S For: Feb 23
Low
Report
Form 6-K NOVO NORDISK A S For: Feb 23
2/23
06:28 am
nvo
Form 6-K NOVO NORDISK A S For: Feb 23
Low
Report
Form 6-K NOVO NORDISK A S For: Feb 23
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/17
Form 6-K NOVO NORDISK A S For: Mar 16
6.0%
3/16 Novo Nordisk A/S (NYSE: NVO) was upgraded by analysts at Bank of America Corp from a "neutral" rating to a "buy" rating. 4.7%
2/5 Q4/2019 12/31/2019 EPS 3.700 ZacksConsensus 0.550 ActVsEst 3.150 - Beat 4.6%
6/8 Novo's oral semaglutide successful in two late-stage T2D studies [Seeking Alpha] 3.8%
11/8 Novo Nordisk: Actual Numbers Not As Good As Headlines But Still Quite Solid [Seeking Alpha] 3.2%
3/27 Form 6-K NOVO NORDISK A S For: Mar 26 3.2%
8/12 Q2/2019 6/30/2019 EPS 4.030 ZacksConsensus 0.610 ActVsEst 3.420 - Beat 3.0%
9/17 With a backup to the backup, insulin makers say they're primed for Brexit [Reuters (UK)] 3.0%
11/1 Form 6-K NOVO NORDISK A S For: Nov 01 2.7%
8/8 Europe stocks climb in early action, led by pharmas [MarketWatch] 2.4%
3/16 Novo Nordisk A/S (NYSE: NVO) was upgraded by analysts at Bank of America Corp from a "neutral" rating to a "buy" rating. 4.7%
2/5 Q4/2019 12/31/2019 EPS 3.700 ZacksConsensus 0.550 ActVsEst 3.150 - Beat 4.6%
6/8 Novo's oral semaglutide successful in two late-stage T2D studies [Seeking Alpha] 3.8%
11/8 Novo Nordisk: Actual Numbers Not As Good As Headlines But Still Quite Solid [Seeking Alpha] 3.2%
3/27 Form 6-K NOVO NORDISK A S For: Mar 26 3.2%
8/12 Q2/2019 6/30/2019 EPS 4.030 ZacksConsensus 0.610 ActVsEst 3.420 - Beat 3.0%
9/17 With a backup to the backup, insulin makers say they're primed for Brexit [Reuters (UK)] 3.0%
11/1 Form 6-K NOVO NORDISK A S For: Nov 01 2.7%
8/8 Europe stocks climb in early action, led by pharmas [MarketWatch] 2.4%
TOP News Decliners
9/9
Form 6-K NOVO NORDISK A S For: Sep 09
-3.6%
11/20 Form 6-K NOVO NORDISK A S For: Nov 20 -2.8%
12/18 Form 6-K NOVO NORDISK A S For: Dec 16 -2.5%
3/9 Form 6-K NOVO NORDISK A S For: Mar 09 -2.4%
4/7 Team Novo Nordisk and Beyond Type 1 Announce New Partnership -2.4%
1/3 Novo Nordisk: A Rare Case of Pharma With Balanced Risk and Reward [Yahoo! Finance News] -2.2%
4/28 Form 6-K NOVO NORDISK A S For: Apr 27 -2.1%
9/10 Novo Nordisk A/S (NYSE: NVO) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. -2.1%
3/23 Form 6-K NOVO NORDISK A S For: Mar 23 -1.8%
10/1 Form 6-K NOVO NORDISK A S For: Sep 30 -1.6%
11/20 Form 6-K NOVO NORDISK A S For: Nov 20 -2.8%
12/18 Form 6-K NOVO NORDISK A S For: Dec 16 -2.5%
3/9 Form 6-K NOVO NORDISK A S For: Mar 09 -2.4%
4/7 Team Novo Nordisk and Beyond Type 1 Announce New Partnership -2.4%
1/3 Novo Nordisk: A Rare Case of Pharma With Balanced Risk and Reward [Yahoo! Finance News] -2.2%
4/28 Form 6-K NOVO NORDISK A S For: Apr 27 -2.1%
9/10 Novo Nordisk A/S (NYSE: NVO) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. -2.1%
3/23 Form 6-K NOVO NORDISK A S For: Mar 23 -1.8%
10/1 Form 6-K NOVO NORDISK A S For: Sep 30 -1.6%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: